anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic renal failure (CRF) is a severe syndrome affecting the urinary system for which there are no effective therapeutics. In this study, we investigate the effects and mechanisms of aminophylline in preventing CRF development. A rat model of chronic renal failure is established by 5/6 nephrectomy. The levels of serum creatinine (SCR), urinary protein (UPR), and blood urea nitrogen (BUN) are detected by ELISA. Histological evaluations of renal tissues are performed by H&E, Masson staining, and PAS staining. Functional protein expression is detected by western blot analysis or immunofluorescence microscopy. Glomerular cell apoptosis is determined using the TUNEL method. Results show that Aminophylline significantly reduces the levels of SCR, UPR, and BUN in the CRF model rats. Histological analyses show that aminophylline effectively alleviates renal tissue injuries in CRF rats. The protein expression levels of nephrin, podocin, SIRT1, p-AMPK, and p-ULK1 are greatly increased, while p-mTOR protein expression is markedly decreased by aminophylline treatment. Additionally, the protein level of LC3B in CRF rats is significantly increased by aminophylline. Moreover, aminophylline alleviates apoptosis in the glomerular tissues of CRF rats. Furthermore, resveratrol promotes SIRT1, p-AMPK, and p-ULK1 protein expressions and reduces p-mTOR and LC3B protein expressions in CRF rats. Selisistat (a SIRT1 inhibitor) mitigates the changes in SIRT1, p-AMPK, p-ULK1, p-mTOR, and LC3B expressions induced by aminophylline. Finally, RAPA alleviates renal injury and apoptosis in CRF rats, and 3-MA eliminates the aminophylline-induced inhibition of renal injury and apoptosis in CRF rats. Aminophylline suppresses chronic renal failure progression by modulating the SIRT1/AMPK/mTOR-mediated autophagy process.
PURPOSE: To report our findings of reduced full-field electroretinograms (ff-ERGs) and abnormal optical coherence tomographic (OCT) images in a patient with poor visual acuity after cataract surgery who was eventually diagnosed with vitamin A deficiency (VAD).
METHODS: This was a clinical study of a patient who complained of blurred vision after cataract surgery. To determine the cause of the reduced vision, we recorded full-field electroretinograms (ff-ERGs) to determine the scotopic and photopic status of the retina. We also performed optical coherence tomography to assess the changes in the retinal structure. Serological tests were performed.
RESULTS: A 74-year-old man presented with persistent corneal epithelial damages and reduced vision that developed after conventional cataract surgery. OCT showed an interrupted ellipsoid zone, and fundus autofluorescence (FAF) showed a severe hypofluorescence in the retina of the left eye. The scotopic ff-ERGs were severely reduced, and the photopic ff-ERGs were mildly reduced. Serological examinations revealed a vitamin A concentration < 7 IU/dL (normal, 97-316 IU/dL). Based on these findings, we diagnosed the patient with VAD and started treatment with oral vitamin A supplements. After three months, his visual acuity, ff-ERGs, and OCT findings recovered to normal levels. The amplitudes and implicit times of the RETeval flicker ERGs increased to be within the normal range, and the hypofluorescence of the left eye disappeared. The length of the photoreceptor outer segments increased after the vitamin A supplementation.
CONCLUSION: Our findings indicate that the ERGs are helpful for diagnosing patients with VAD associated with persistent corneal epithelial damages.
Participants in the intervention group will complete baseline questionnaires and receive instructions on how to download Powerly. They will use the app daily for 28 days, at least once per day, and will be invited to complete the questionnaires again, and once more six weeks postpartum.
MED-LFD Diet (diet A) for 2 - 6 weeks. After this period there will be a reintroduction phase protocol that will last 6 - 8 weeks.
The invention relates to a method and composition for reducing levels of IgM, IgG or IgA in mammals. This method provides administering a BLyS antagonist which is a TACI-Fc-fusion protein comprising the polypeptide sequence of SEQ ID NO: 23, wherein the modified signal sequence of tissue plasminogen activator (SEQ ID NO: 41) and mycophenolate mofetil (MMF) has been removed from said polypeptide sequence. Said BLyS antagonist and MMF are administered in an amount which acts synergistically to reduce immunoglobulin levels, i.e. the BLyS antagonist is administered at a dosage of 0.25-25 mg/kg and the MMF is administered at a dosage of 500-1000 mg/kg. Said mammal has a B-cell regulated autoimmune disorder arising from antibodies that are directed against the mammal's own (self) antigens or tissues. The composition used to reduce immunoglobulin levels comprises said BLyS antagonist and mycophenolate mofetil.
Capecitabine, an oral fluoropyrimidine, has shown a comparable efficacy but a better tolerability compared to bolus 5-FU/LV. However, capecitabine has a higher incidence of hand-foot syndrome (HFS). HFS is characterized by erythema, dysesthesia and/or paresthesia of the palms of the hands or soles of feet. In advanced stage, desquamation, ulceration and blistering can occur. Although HFS is not life threatening, it can cause significant discomfort and impairment of function, especially in elderly patients. This adverse event is becoming particularly relevant since many patients may require the administration of capecitabine over prolonged periods of time.

S-1 (Teysuno®) is an oral fluoropyrimidine that has shown comparable efficacy to 5FU and capecitabine in gastrointestinal cancers but is associated with a much lower incidence of HFS. Studies on S-1 have mainly been performed in Asian patients,which population has known differences in tumour biology and toxicity compared to Western population. S-1 has shown comparable efficacy to other fluoropyrimidines as monotherapy or in combination chemotherapy schedules in several gastrointestinal tumors. However, given the lack of data from prospective studies on S-1 as monochemotherapy in metastatic colorectal cancer in Western patients, this study is designed to compare S-1 and capecitabine monotherapy in terms of safety, with particular interest in HFS, in metastatic colorectal cancer patients.
Geriatric patients (those 65 years of age and older), compared to younger adult patients, are at greater risk for NSAID-associated serious cardiovascular, gastrointestinal, and/or renal adverse reactions [see Warnings and Precautions (5.2, 5.3, 5.7)]. In addition, the risk of diclofenac-associated adverse reactions may be greater in geriatric patients with renal impairment or those taking concomitant ACE inhibitors or ARBs [see Drug Interactions (7) and Use in Specific Populations (8.6)].

Avoid use of ARTHROTEC in geriatric patients with cardiovascular and/or renal risk factors. If use cannot be avoided, use the lowest recommended dosage for the shortest duration and monitor for cardiac and renal adverse reactions [see Dosage and Administration (2.1)]. Monitor renal function in geriatric patients during treatment with ARTHROTEC, especially in patients with concomitant use of ACE inhibitors or ARBs.

Of the 2,184 patients in clinical studies with ARTHROTEC, 557 (25.5%) were 65 years of age and over. No overall differences in effectiveness were observed between these patients and younger adult patients, and other reported clinical experience has not identified differences in effectiveness between geriatric patients and younger adult patients, but greater sensitivity of some older individuals cannot be ruled out.

No clinically meaningful differences in the pharmacokinetics of diclofenac and misoprostol were observed in geriatric patients compared to younger adult patients [see Clinical Pharmacology (12.3)].
An application of circular RNA to regulation and control of pancreatic islet β cell proliferation. The nucleotide sequence of the circular RNA is as shown in SEQ.ID.NO. 1 or SEQ.ID.NO. 2. Overexpression of the circular RNA can effectively promote proliferation of mouse pancreatic islet β cells, and knockout of the circular RNA can effectively inhibit proliferation of the mouse pancreatic islet β cells, so that the circular RNA can be used for preparing drugs for treating diabetes or pancreatic islet β cytosis. A series of experiments prove that the circular RNA can effectively promote proliferation of pancreatic islet β cells, and essentially proves that the circular RNA has a wide application background in treatment of insufficiency in insulin secretion caused by reduction of the number of pancreatic islet β cells. The present invention can provide a good candidate drug for clinical treatment of diabetes caused by reduction of the number of islet β cells, and has a very good application prospect.
Patients receive oral temozolomide on days 1-5. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
The invention relates to a computer-implemented method for providing error information about a plurality of individual measurements. The method comprises a method step of providing (PROV-1) a plurality of individual measurements, each of which is assigned to a test. The method further comprises a method step of Receiving (REC) inspection information from a user via an interface regarding the population to be inspected under inspection. For each examination of the population, the method further comprises the method steps of Extracting (EXT) examination information based on the individual measurements belonging to the examination, determining (DET-1) whether one or more erroneous measurements were made in the examination based on the examination information, and deriving (DET-2) examination error information based on the result of the determination. The method further comprises a method step of compiling (DET-3) error information based on the checked error information of the population to be checked. The method further comprises the method step of providing (PROV-2) error information to the user via the interface.
3-Methyl-1-pentyn-3-ol is reacted with phthalic anhydride in the presence of pyridine.  The cooled reaction mixture is diluted with water, acidified with hydrochloric acid and allowed to crystallize to give 3-methyl-1-pentyn-3-yl acid phthalate <FORM:0767777/IV(b)/1> This compound may be reacted with sodium carbonate, potassium carbonate, calcium carbonate, ammonia, monoethanolamine, diethanolamine and ethylene diamine to give the respective salts. The acid phthalate and/or its salts may be used as anthelminthics in medicine (see Group VI).ALSO:Compositions for combating Trichuris infection of mammals comprise 3 - methyl-1 - pentyn - 3 - yl phthalate  <FORM:0767777/VI/1> and/or non toxic salts thereof.  A non-toxic pharmaceutical carrier which may be water, glycerol, non-toxic glycols, alcohol or mixtures thereof: or talc, lactose, corn starch, stearic acid, magnesium stearate, methyl cellulose and vegetable gums may also be present.  The preparation may be in the form of a solution, suspension, tincture, elixir or emulsion or tablet, capsule, powder, soft pill or coated granule.  In an example 3 - methyl - 1 - pentyn - 3 - yl acid phthalate is granulated with starch and acacia, the granules mixed with starch, talc and magnesium stearate and the mixture tabletted.
Responders at week 24 continue treatment with adalimumab. Non-responders at week 24 stops treatment with adalimumab.
Participants received 1 single dose of PF-04958242 0.35 mg, PF-04958242 0.6 mg, and placebo orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
The Zwolle risk score was designed to stratify in-hospital mortality risk of ST-elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (pPCI) and for decision-making in the unit where patients are admitted. We assessed the accuracy of Zwolle risk score for in-hospital mortality estimation compared with the GRACE score in all patients (n = 4446) admitted for STEMI in 3 university hospitals. Only one fourth of the patients were classified as high-risk by the Zwolle risk score vs 60% by the GRACE score. In-hospital mortality was 10.6%. A statistically significant increase in in-hospital mortality, adjusted by age, gender, and revascularization, was observed with both scores. The assessment of the optimal cut-off points verified the accuracy of Zwolle score ≥4 as optimal threshold for high-risk categorization. In contrast, GRACE score ≥140 had very low specificity as well as percentage of patients correctly classified; GRACE score ≥175 was fairly better. The reclassification index of the Zwolle score after applying the GRACE score was 35.5%. Selection of high-risk STEMI patients treated with pPCI based on the Zwolle risk score has higher specificity than the GRACE score and might be useful in clinical practice.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to experimental surgery. Use the device for the injury of small laboratory animals by the "blow" mechanism, namely the traumatic impact of a cargo weighing 425 g, which falls from a height of 28 cm and transfers its energy to the anterior abdominal wall of a laboratory rat weighing 360–390 g, lying in a supine position with the orientation of the center of the shock pad with a diameter of 3.5 cm 5 mm to the right and above the tip of the xiphoid process. 1 ml of blood is taken from the carotid artery immediately before the injury and 60 minutes after it for 1 minute, which simulates excessive bleeding from the liver vessels immediately after the injury and its amplification during laparotomy, when a revision of the abdominal cavity is performed. Necessity of such sampling is dictated by the faster formation of fibrin in rats and, as a consequence, an earlier stop of bleeding compared with a human, even with massive liver damage. First 20 minutes after the injury simulate the situation of waiting for medical care to the victims, so there is no fluid resuscitation, which corrects hypotension. Prehospital phase is modeled from 20 to 60 minutes, when the patient receives infusion therapy with maintaining systolic blood pressure at the level of 80–90 mm Hg and is delivered to the hospital. By the 60minute, a laparotomy is performed, and one or another surgical technique is performed. Study of the hemostasis system showed the presence of coagulopathy after such an injury by 60minute.EFFECT: method allows to create a model of a closed blunt severe liver injury with coagulopathy in small laboratory animals, which is closest to the real situation in life.1 cl, 1 ex
BACKGROUND: Malnutrition frequently is associated with increased complications and worse outcomes after surgery. The purpose of this study was to determine whether malnutrition status determined using the Geriatric Nutritional Risk Index (GNRI) can serve as an independent risk factor for complications in patients undergoing anterior cervical discectomy and fusion (ACDF).
METHODS: The American College of Surgeons National Surgical Quality Improvement Program database was queried from 2011 to 2016 for patients age ≥65 years who underwent ACDF. Patients were categorized into 3 groups based on the GNRI: >98, normal nutritional status; 92-98, moderately malnourished; and <92, severely malnourished. Multivariate logistic regression models adjusted for covariates of demographics, comorbidities, and operative metrics were used to evaluate GNRI as an independent risk factor for postoperative outcomes.
RESULTS: A total of 3148 patients who underwent ACDF were analyzed, of whom 78.9% had normal nutrition, 16.1% were moderately malnourished, and 5.0% patients were severely malnourished. On multivariate analysis, moderate and severe malnutrition were found to be independent risk factors for any complication, pulmonary complications, pneumonia, unplanned intubation, and hospital length of stay >6 days (P < 0.05 for all). In addition, moderate malnutrition was a risk factor for failure to wean from ventilation for >48 hours and 30-day readmission. Severe malnutrition was an independent risk factor for septic shock and nonhome discharge.
CONCLUSIONS: In elderly patients after ACDF, malnutrition determined using GNRI is an independent risk factor for 30-day complications, readmissions, prolonged hospital length of stay, and nonhome discharge.
When performing lumpectomy, surgeons have used electrocautery devices as dissecting tools. However, those devices use high thermal energy that might impact the margin cellular architecture and as such the quality of margin assessment by the pathologist. Moreover, recently, modern low thermal energy dissection devices have been introduced to the market. However, the impact of those devices on reducing the thermal injury/artifact on surgical margin has not been well investigated. 4,5 While Ruidaz et al. 2011 data suggest that using the traditional electrosurgical device in place of the low thermal-injury device results in 48% of the close margin samples being negatively converted to false-positive, and in 11% converting from close to false-negative, there is still a need for more studies to further characterize the utility of those devices. 6 PhotonBlade (Invuity, San Francisco, CA, USA) has been approved by United States Food and Drug Administration (FDA). PhotonBlade is a dynamic precision illuminator with enhanced energy delivery dissection device. The dynamic precision illumination is a thermally cool illumination technology that allows a uniformal illumination without glare or shadow. 7 The enhanced energy delivery technology allows low thermal spread, surgeon controlled edge temperature, and wet field use.7 As such, PhontonBlade allows better blade control for achieving adequate visualization, hemostasis, with a minimum collateral damage to the surgical margin tissue. The use of PhotonBlade demonstrated the least penetrating thermal tissue damage/spread when compared to other modern dissection devices (Valleylab Pencil, Valleylab EDGE Coated Pencil, PlasmaBlade 3.0S and PlasmaBlade 4.0).8
INTRODUCTION: The management of spinal sarcomas is complex, given their widespread involvement and high recurrence rates. Despite consensus on the need for a multidisciplinary approach with surgery at its core, there is a lack of definitive guidelines for clinical decision-making. This study examines a case series of primary spinal sarcomas, focusing on the surgical strategies, clinical results, and survival data to inform and guide therapeutic practices.
METHODS: We conducted a retrospective analysis of patients who underwent surgical resection for primary spinal sarcomas between 2005 and 2022. The study focused on gathering data on patient demographics, surgical details, postoperative complications, overall hospital stay, and mortality within 90 days post-surgery.
RESULTS: The study included 14 patients with a primary diagnosis of spinal sarcoma, with an average age of 48.6 ± 12.6 years. Chondrosarcoma emerged as the most common tumor type, representing 57.1% of cases, followed by Ewing sarcoma at 35.7%, and synovial sarcoma at 7.1%. Patients with chondrosarcoma were treated with en-bloc resection, while the patient with synovial sarcoma underwent intra-lesional excision and those with Ewing sarcoma received decompression and tumor debulking. Postoperative assessments revealed significant improvements in neurological conditions. Notably, functional status as measured by the Karnofski Performance Index (KPI), improved substantially post-surgery (from 61.4 to 80.0%) The mean follow-up was 34.9 ± 9.2 months. During this time period one patient experienced fatal bleeding after en-bloc resection complications involving the vena cava. None of the patient needed further surgery.
CONCLUSIONS: Our 16-year study offers vital insights into managing primary spinal sarcomas, showcasing the effectiveness of surgical intervention, particularly en-bloc resection. Despite their rarity and complexity, our multidisciplinary treatment approach yields improved outcomes and highlights the potential for refined surgical strategies to become standardized care in this challenging domain.
Home care management tasks may be tracked, scheduled, verified, and accounted for using devices interacting with each other to maintain an overall “care plan” for a given care recipient (“CR”). The CR represents a patient in need of home health services (or other support services) that may be provided by a group of actors connected virtually through a computer managed network providing a care management system. The care management system includes logic and devices that interact to create an automated care plan. Data underlying the care plan is secure and protected (e.g., follows HIPAA rules). A matrix of access permissions is maintained based on actors, roles of actors, and type of data maintained. Actors may be family members, volunteers, medical professionals, or other service providers. Location data for an actor may determine when or if an alert style notification is sent to a device associated with that actor.
PURPOSE: To obtain a solidifying agent for a silicone oil which has thixotropic properties and can gelatinize a silicone oil by using a specific organopolysiloxane having both molecular ends modified. CONSTITUTION: The agent contains an organopolysiloxane of the formula having both molecular ends modified. In the formula, R<1> to R<4> are each independently 1-6C alkyl, phenyl, or naphthyl; R<5> and R<6> are each independently a 16-600C linear or branched satd. hydrocarbon group; and r and s are each 0 or higher. Though the agent may comprise the organopolysiloxane alone, it may further contain other ingredients (e.g. a wax or an oil-gelatinizing agent) if necessary. A stable cosmetic excellent in persistence, feeling in use, etc., can be formed by incorporating the agent into a silicone oil liq. at normal temp.
FIELD: medicine. SUBSTANCE: method involves taking samples of materials removed from uterine cavity in the amount of enough for revealing infection agents transferred in sexual way. The infection having been revealed, non-specific antibacterial therapy is to be substituted with antibacterial therapy taking into account the detected infectious agent in combination with non- specific immunity-stimulating therapy. The process is regularly continued by controlling patient state until complete recovery is achieved. Complex clinical laboratory study is carried out for detecting the infectious agents transferred in sexual way and controlling recovery degree. The study comprises at least two diagnosis methods selected from the following row: bacterioscopy, cultural method, immunoenzyme analysis and polymerase chain reaction method. EFFECT: accelerated treatment course.